Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miconazole nitrate + zinc oxide
- Development stage
- Approved
- Lead developer
- Viatris
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
A topical combination medication primarily used to treat diaper rash complicated by fungal infections. This topical preparation combines the antifungal properties of miconazole with the protective and soothing effects of zinc oxide. Specifically indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (yeast infection). It is approved for use in infants 4 weeks of age and older with normal immune systems.
- Brand names
- VusionRash Relief AntifungalDaktozin
- Other names
- miconazole nitrate, zinc oxide, and white petrolatum
02
Targets
CYP51A1 (Sterol 14α-demethylase)
Beyond the preview
Go deeper on miconazole nitrate + zinc oxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miconazole nitrate + zinc oxide.